IMUC Demonstrates Impressive Survival Data |
 |
 |
| By Staff and Wire Reports | |
| Wednesday, 02 June 2010 08:19 | |
|
They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy. "We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer. A year after diagnosis, all of the patients were alive. After two years, 80 percent of them were alive. Historically, after a year with standard treatment, 61 percent of glioblastoma patients are alive, and 26.5 are alive after two years, according to the company. “These new data further establish ICT-107 as a promising potential treatment for glioblastoma, a disease for which there are currently few and limited treatment options,” said Surasak Phuphanich, M.D., Director of the Neuro-Oncology Program at Cedars-Sinai Medical Center. “We are excited for what these data mean for patients, the medical community, and the field of immunotherapy as a whole. We look forward to further investigating ICT-107 in additional clinical studies.” In the ImmunoCellular trial, median overall survival had not yet been reached at the 26.4 months analysis point, with 12 out of 16 patients alive. Seven patients continued to live with no disease progression.
Yu said ImmunCellular is planning a mid-stage trial of the vaccine that would include between 30 and 50 patients. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
As subscribers to BioMedReports 
Free Phone Trade Alerts
